Recombinant human urokinase

DRUG2 trials

Sponsors

Tasly Biopharmaceuticals Co., Ltd.

Conditions

Acute Ischaemic Stroke

Phase 3

Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)

CompletedNCT03541668

Tasly Biopharmaceuticals Co., Ltd.Acute Ischaemic Stroke

Start: 2018-05-18End: 2020-05-24Updated: 2020-06-22

Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial

CompletedNCT03578822

Tasly Biopharmaceuticals Co., Ltd.Acute Ischaemic Stroke

Start: 2018-08-10End: 2020-03-01Updated: 2020-04-28

Related Papers

Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Ischemic Stroke Within 4.5 Hours of Stroke Onset

JAMA Network Open2023-07-2541 citations